The capacity to fine-tune cellular bioenergetics with the demands of stem-cell maintenance and regeneration is central to normal development and ageing, and to organismal survival during periods of acute stress. How energy metabolism and stem-cell homeostatic processes are coordinated is not well understood. Lkb1 acts as an evolutionarily conserved regulator of cellular energy metabolism in eukaryotic cells and functions as the major upstream kinase to phosphorylate AMP-activated protein kinase (AMPK) and 12 other AMPK-related kinases 1-3 . Whether Lkb1 regulates stem-cell maintenance remains unknown. Here we show that Lkb1 has an essential role in haematopoietic stem cell (HSC) homeostasis. We demonstrate that ablation of Lkb1 in adult mice results in severe pancytopenia and subsequent lethality. Loss of Lkb1 leads to impaired survival and escape from quiescence of HSCs, resulting in exhaustion of the HSC pool and a marked reduction of HSC repopulating potential in vivo. Lkb1 deletion has an impact on cell proliferation in HSCs, but not on more committed compartments, pointing to context-specific functions for Lkb1 in haematopoiesis. The adverse impact of Lkb1 deletion on haematopoiesis was predominantly cellautonomous and mTOR complex 1 (mTORC1)-independent, and involves multiple mechanisms converging on mitochondrial apoptosis and possibly downregulation of PGC-1 coactivators and their transcriptional network, which have critical roles in mitochondrial biogenesis and function. Thus, Lkb1 serves as an essential regulator of HSCs and haematopoiesis, and more generally, points to the critical importance of coupling energy metabolism and stem-cell homeostasis.
The capacity to fine-tune cellular bioenergetics with the demands of stem-cell maintenance and regeneration is central to normal development and ageing, and to organismal survival during periods of acute stress. How energy metabolism and stem-cell homeostatic processes are coordinated is not well understood. Lkb1 acts as an evolutionarily conserved regulator of cellular energy metabolism in eukaryotic cells and functions as the major upstream kinase to phosphorylate AMP-activated protein kinase (AMPK) and 12 other AMPK-related kinases [1] [2] [3] . Whether Lkb1 regulates stem-cell maintenance remains unknown. Here we show that Lkb1 has an essential role in haematopoietic stem cell (HSC) homeostasis. We demonstrate that ablation of Lkb1 in adult mice results in severe pancytopenia and subsequent lethality. Loss of Lkb1 leads to impaired survival and escape from quiescence of HSCs, resulting in exhaustion of the HSC pool and a marked reduction of HSC repopulating potential in vivo. Lkb1 deletion has an impact on cell proliferation in HSCs, but not on more committed compartments, pointing to context-specific functions for Lkb1 in haematopoiesis. The adverse impact of Lkb1 deletion on haematopoiesis was predominantly cellautonomous and mTOR complex 1 (mTORC1)-independent, and involves multiple mechanisms converging on mitochondrial apoptosis and possibly downregulation of PGC-1 coactivators and their transcriptional network, which have critical roles in mitochondrial biogenesis and function. Thus, Lkb1 serves as an essential regulator of HSCs and haematopoiesis, and more generally, points to the critical importance of coupling energy metabolism and stem-cell homeostasis.
HSCs function to replenish the blood system and maintain haematopoietic homeostasis in response to either physiological or imposed stress demands [4] [5] [6] . To explore the role of Lkb1 in various aspects of HSC biology, we assessed the impact of somatic deletion of Lkb1 in the mouse adult haematopoietic system using Rosa26-creERt2 deleter mice 7 . In this model, the treatment of adult mice with tamoxifen results in complete deletion of Lkb1 in haematopoietic organs (Supplementary Fig. 1a ) and associated reductions of phosphorylation of AMPK Thr 172 and AMPK substrate acetyl-CoA carboxylase (ACC) Ser 79 ( Supplementary Fig. 1b ). Notably, within 30 days post completing tamoxifen injection (d.p.i.), all tamoxifen-treated Lkb1 L/L ; Rosa26-creERt2 mice (hereafter referred to as Lkb1 knockout) exhibited constitutional signs of weight loss ( Supplementary Fig. 2a ), lethargy, hunched posture and ultimately death ( Fig. 1a) ; in contrast, tamoxifentreated Lkb1 1/1 ; Rosa26-creERt2 or Lkb1 L/L mice (collectively referred to as Lkb1 wild type hereafter) remained viable and healthy ( Fig. 1a ).
Somatic deletion of Lkb1 led to pancytopenia within 1 week after tamoxifen treatment (7 d.p.i.), as shown by reduced weight of spleen and thymus, and reduction of the absolute cell number of bone marrow, spleen and thymus ( Supplementary Fig. 2b-f ). Lkb1 knockout mice also developed acute anaemia as shown by a marked decline in red blood cell, haemoglobin and haematocrit counts (Supplementary Figs 2g-i).
Although anaemic, Lkb1 knockout mice had increased non-fasting blood glucose levels ( Supplementary Fig. 3 ), making it unlikely that the Lkb1 knockout anaemia phenotype derives from a profound systemic deficiency in glucose availability. Further analysis revealed severe reductions in Lkb1 knockout Ter119 1 cells and erythroid progenitors at all developmental stages ( Fig. 1b and Supplementary  Fig. 4a, b ). Consistent with the pancytopenia phenotype described above, we observed a decline of all haematopoietic lineages examined in the Lkb1 knockout mice, including platelets ( Supplementary Fig.  4c ), Gr-1 1 /Mac-1 1 cells ( Fig. 1c and Supplementary Fig. 4d ), B cells ( Fig. 1d and Supplementary Fig. 4e ) and T cells ( Supplementary Fig.  4f ). To study the underlying mechanism of the multi-lineage defects associated with Lkb1 deletion, we examined the cell survival status of various lineages in Lkb1 wild-type and knockout mice given the important role of Lkb1 in the maintenance of cell survival under energy stress in other cellular contexts 8, 9 . Indeed, we observed an increase of cleaved caspase-3 in Lkb1 knockout bone marrow, spleen and thymus samples ( Supplementary Fig. 5 ). Further annexin-V/7aminoactinomycin D (7AAD) analysis revealed increased apoptosis in myeloid, erythroid and B-cell populations in Lkb1 knockout bone marrow cells (Fig. 1e ). In summary, Lkb1 deficiency leads to a severe pancytopenia phenotype and impairs the cell survival of multiple lineages.
Next we examined HSC and haematopoietic progenitor populations in Lkb1 knockout mice. Compared with wild-type controls, serial analysis of Lkb1 knockout HSC-enriched LSK cells (Lin 2 , Sca-1 1 , c-Kit 1 ) and long-term HSCs (LT-HSCs; CD34 2 Flt-3 2 LSK cells) in bone marrow showed an acute increase at 1 d.p.i., but a subsequent decrease in numbers from 4 d.p.i. and thereafter ( Fig. 2a, b ). A 5-bromodeoxyuridine (BrdU) labelling experiment revealed a significantly increased percentage of BrdU-positive cells in Lkb1 knockout LSK cells ( Fig. 2c and Supplementary Fig. 6a, b ). Notably, Lkb1 deletion increased cell proliferation only in LSK and LSK CD34 2 cells, but not whole bone marrow and mature lineage cells ( Fig. 2c ), indicating an HSC-specific role for Lkb1 in the regulation of cell quiescence. The more pronounced function of Lkb1 in the HSC compartment also aligns well with its more prominent expression levels in HSCs relative to other more committed compartments ( Supplementary Fig. 6c, d ). Furthermore, annexin-V/ 7AAD staining of the LSK population showed increased apoptosis in Lkb1 knockout LSK cells ( Supplementary Fig. 6e , f). Together, our results indicate that Lkb1 functions to maintain HSC quiescence and survival and that Lkb1 inactivation leads to transient expansion, yet subsequent decline, of bone marrow HSCs.
We next performed competitive and non-competitive transplantation assays to examine the impact of Lkb1 deficiency on HSC repopulating capability in vivo ( Supplementary Fig. 7a, b ). In the competitive transplantation experiments, we observed that Lkb1 knockout transplants showed markedly diminished repopulating capability relative to wild-type controls ( Fig. 2d and Supplementary Fig. 8a-c ). In the noncompetitive experiments, all recipient mice reconstituted with Lkb1 L/L ; Rosa26-creERt2 bone marrow cells died within 60 d.p.i. (Supplementary Fig. 8d ) with anaemia, pancytopenia defects (data not shown) and increased HSC cell-cycle entry and subsequent decline (Supplementary Fig. 8e , f). These data collectively indicate that Lkb1 exerts a predominant cell-autonomous impact on haematopoietic repopulating potential and homeostasis.
To understand the mechanisms underlying Lkb1-directed regulation of HSC homeostasis, we assessed the impact of pharmacological inhibition of mTORC1 signalling on the Lkb1 knockout phenotype, given that mTORC1 serves as a key downstream surrogate of Lkb1-AMPK signalling 3 and also has critical roles in the regulation of HSC homeostasis [10] [11] [12] [13] [14] . Daily rapamycin or vehicle protocols were initiated to Lkb1 or Tsc1 wild-type and knockout mice at the time of tamoxifen treatment 12 . Rapamycin treatment significantly rescued multi-lineage defects, HSC cycling increase and expansion phenotypes in Tsc1 knockout mice, but had minimal effect on these phenotypes in Lkb1 knockout mice ( Fig. 3a -c) despite confirmation of abolished S6 phosphorylation in sorted bone marrow B220 1 cells, Mac1 1 cells and CD34 2 LSK cells from Lkb1 knockout mice ( Supplementary Fig. 9 ). Thus, unlike Tsc1, Lkb1 regulates haematopoiesis via an mTORC1independent pathway. Finally, administration of metformin, a known AMPK activator, did not rescue bone marrow/thymus cellularity decline, LSK transient expansion/subsequent depletion phenotype and lineage defects in Lkb1 knockout mice ( Supplementary Fig. 10 ). These data, together with AMPK activator A-769662 treatment data from ref. 15 and AMPK knockout mice analyses from ref. 16 , indicate that either multiple AMPK-related kinases (including AMPK) cooperatively mediate Lkb1 function in HSC homeostasis or that non-AMPK-dependent processes are operative.
The above observations prompted us to carry out transcriptome analysis of sorted LSK cells from Lkb1 wild-type and knockout bone marrow at 1 d.p.i. to gain further mechanistic insight of Lkb1 regulation of HSC homeostasis ( Supplementary Fig. 11a ). Ingenuity pathway analysis of 570 significantly differentially expressed genes revealed significant enrichment of genes involved in G1/S cell-cycle checkpoint regulation ( Supplementary Fig. 11b and Supplementary Table 1 ) including upregulation of cyclin D1, cyclin D2, cyclin E1, Cdc25A, E2F1, Cdk4 and Skp2, which would serve to synergistically promote cell cycling of Lkb1 knockout LSK cells. Most notably, there was prominent representation of LXR/RXR, VDR/RXR and PPAR metabolism pathways ( Supplementary Fig. 11b ). To identify key networks regulated by Lkb1 in a Tsc-mTORC1-independent manner, we further conducted comparative analysis of Lkb1 and Tsc1 (ref. 12) HSC transcriptome data sets ( Supplementary Fig. 11a ), which revealed that, although G1/S cell-cycle checkpoint was enriched in both data sets, the LXR/RXR, VDR/RXR and PPAR metabolism pathways were distinctively enriched in the Lkb1 transcriptome data set ( Supplementary Fig. 11c ). In addition, promoter analysis of the Lkb1 HSC transcriptome data set identified E2F, nuclear respiratory factor 1 (Nrf1) and PPAR-c motifs as the most significantly enriched promoter binding elements in the Lkb1 LSK transcriptome data set (1.43, 2.13 and 1.43, respectively). The link to PPAR-c and Nrf1 is notable given that the peroxisome proliferator-activated receptor-coactivators PGC-1a and PGC-1b are the principal transcriptional coactivators for PPAR-c and Nrf1 (ref. 17) , and that the PGC-1s are regulated by Lkb1 (ref. 18) .
Prompted by this observation, we next investigated whether deletion of Lkb1 has an impact on PGC-1-a master transcriptional regulator of mitochondrial biogenesis 19 -and its associated biological processes in the haematopoietic system. We found that the expression levels of both PGC-1a and PGC-1b were downregulated in Lkb1 
RESEARCH LETTER
knockout LSK cells (Fig. 4a ), which coincided with decreased mitochondrial membrane potential and DNA content in Lkb1 knockout LSK cells at 4 d.p.i. (Fig. 4b, c) . Interestingly, we observed increased mitochondrial DNA content in Lkb1 knockout LSK cells at a later time point (10 d.p.i.), possibly reflecting compensatory (secondary) effects that occur in the wake of mitochondriopathy (Fig. 4c ). Finally, we found that the basal ATP levels in spleen and thymus were profoundly decreased in Lkb1 knockout mice (Fig. 4d ). Although our data raise the possibility that Lkb1 deficiency and associated dysregulation of PGC-1 impair mitochondrial function, the presence of apoptosis in these Lkb1 2/2 HSCs does not allow us to exclude the possibility that mitochondrial dysfunction reflects, in part, an ongoing apoptotic process caused by Lkb1 deletion.
Our results reveal an essential role of Lkb1 in the maintenance of HSC homeostasis. Somatic deletion of Lkb1 in the haematopoietic system impairs HSC quiescence and survival and leads to metabolic catastrophe, resulting in pancytopenia and rapid animal death.
Mechanistically, we propose that Lkb1 maintains HSC homeostasis through multiple mechanisms governing mitochondrial function, cell survival and cell-cycle regulation via Lkb1 regulation of AMPK and other AMPK-related kinases and their downstream effectors (including PGC-1). Our findings align with those of two accompanying papers 15, 16 and provide a broad framework to understand the integration of energy signalling and mitochondrial physiology in the maintenance of HSC homeostasis.
METHODS SUMMARY
The Lkb1 L/L mice were described previously 20 . Rosa26-creERt2 mice were provided by A. Berns 7 . Lkb1 L/1 ; Rosa26-creERt2 1 mice were backcrossed six generations into a C57BL/Ka-CD45.2:Thy-1.1 background, which were then intercrossed to generate mice of the desired genotypes. Recipients in transplantation assays were adult C57BL/Ka-CD45.1:Thy-1.2 mice (Jackson Laboratory). Tamoxifen treatment, phenotypic analyses of mice, rapamycin administration, flow cytometric analysis and transplantation assays were performed as previously described 12 . All animal manipulations were performed with Harvard/DFCI's Institutional Animal Care and Use Committee (IACUC) approval. For microarray analysis, the RNA from sorted LSK cells (10,000-20,000) was extracted and the cDNA was analysed on the Affymetrix 430 2.0 platform. Quantitative real-time PCR was performed on the Stratagene Mx3000P using the Quantitative SYBR green PCR kit. Lkb1 WT 
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METHODS Generation and analysis of mice. Lkb1 L/L mice were crossed with Rosa26-creERt2 mice to generate Lkb1 L/1 ; Rosa26-creERt2 mice. Lkb1 L/1 ; Rosa26-creERt2 1 mice were backcrossed six generations into the C57BL/Ka-CD45.2:Thy-1.1 background, which were then intercrossed to generate mice of the desired genotypes. Recipients in transplantation assays were adult C57BL/Ka-CD45.1:Thy-1.2 mice (Jackson Laboratory). Tamoxifen treatment of mice was done as previously described 12 . Briefly, littermates at 4-6 weeks of age were administered daily by intraperitoneal injection of tamoxifen (Sigma) in corn oil (12 mg ml 21 in corn oil) at 132 mg tamoxifen per gram of body weight per day for five consecutive days. Animals were autopsied and all tissues were examined regardless of their pathological status. Tissue samples were fixed in 10% neutral-buffered formalin (Sigma) overnight, and washed once with 13 PBS and then transferred into 70% ethanol and stored at 4 uC. Tissues were processed by ethanol dehydration and embedded in paraffin according to standard protocols. Sections (5 mm) were prepared for antibody detection and haematoxylin and eosin staining. Blood glucose level was measured by Ascensia ELITE Blood Glucose Meter (3873A) following the manufacturer's instruction. All animal manipulations were performed with Harvard/DFCI's Institutional Animal Care and Use Committee (IACUC) approval. Flow cytometry analysis. Single-cell suspensions were prepared from spleen, thymus and bone marrow (from femoral and tibial bones) by passing cells through a 70-mm cell strainer. Cells were lysed on ice with red blood cell lysis solution (Sigma), washed in PBS 12% FCS, then re-suspended in PBS 12% FCS. Cell numbers were subsequently counted. Cells were incubated with fluorochromeconjugated (or with biotin-conjugated) antibodies (CD4, CD8, Ter119, Gr-1, Mac-1, B220, Kit, Sca-1, CD34, Flt3, and so on) for 30 min on ice, followed by washing once in PBS 12% FCS. For lineage marker labelling, cells were stained with other fluorochrome-conjugated antibodies and biotin-conjugated lineage markers (CD3, B220, Gr-1, Mac-1, Ter119) (BD Bioscience) for 30 min on ice, followed by incubation with fluorochrome-conjugated Streptavidin (BD Bioscience) for 5 min. For the analysis of bone marrow lymphopoiesis, cells were stained with fluorochrome-conjugated anti-B220, CD19, CD43, IgM and biotinconjugated lineage markers (CD3, Gr-1, Mac-1, Ter119) (BD Bioscience) for 30 min on ice, followed by incubation with fluorochrome-conjugated Streptavidin for 5 min. LSK and LT-HSC populations were analysed and sorted using FACSAria (Becton Dickinson) as previously reported 21 . For mitochondrial membrane potential measurement, bone marrow cells stained for LSK populations were incubated with 50 mM DilC-5 (Invitrogen) at 37 uC for 15-30 min. Apoptosis was determined by staining freshly harvested bone marrow mononuclear cells with lineage, stem and progenitor markers, followed by Annexin-V-FITC and 7AAD staining (BD Bioscience). Cell cycle analysis was carried out as previously reported using the FITC BRDU Flow Kit (BD Bioscience) 22 . Additional analyses were carried out on a 4-colour FACSCalibur cytometer (Becton Dickinson) with a minimum of 10,000 events acquired. The data were analysed by FlowJo and CellQuest software.
Competitive and non-competitive repopulation assays. In non-competitive repopulation assay, 1 3 10 6 bone marrow cells from both Lkb1 L/L ; Rosa26-creERt2 or littermate wild-type (Lkb1 1/1 ; Rosa26-creERt2 or Lkb1 L/L ) mice (both CD45.2 1 ) were injected into lateral tail veins of lethally irradiated CD45.1 1 recipient animals. In the competitive repopulation assay, an appropriate amount of bone marrow cells from both Lkb1 L/L ; Rosa26-creERt2 or littermate wild-type mice (both CD45.2 1 ) were mixed with bone marrow cells from CD45.1 1 wild-type mice (totally 1 3 10 6 ), then injected into lateral tail veins of lethally irradiated CD45.1 1 recipient animals (950 rad in two dosages, 2 h apart). Five to six weeks after transplantation, when these mice showed stable chimaerism, Lkb1 was deleted by tamoxifen treatment. Peripheral blood was collected at 4, 8 and 16 weeks after tamoxifen treatment, and bone marrow from mice at 16 weeks was analysed for contribution of CD45 congenic and lineage markers by flow cytometry. Tissues from the recipient mice at 16 weeks were collected for further analyses, including cell surface marker staining by flow cytometry, histology characterization, and so on. Both non-competitive and competitive transplants were carried out with three-five donors per genotype with three recipient mice per donor in each experiment. Administration of rapamycin. At the time of tamoxifen treatment, mice were administered with rapamycin (LC laboratories) by daily intraperitoneal injection at 4 mg per gram of body weight per day. After tamoxifen treatment was finished, mice were treated with rapamycin for another 1-10 days and subjected to various phenotypic analyses. Rapamycin was first reconstituted in absolute ethanol at 25 mg ml 21 and then diluted in 5% Tween-80 and 5% PEG-400 before injection to make 0.5 mg ml 21 solution for injection. Administration of metformin. At the time of tamoxifen treatment, mice were administered metformin (Sigma) by daily intraperitoneal injection at 250 mg
